USP 795 and 797 Peptide Documentation Guide

What USP 795 and 797 Peptide Documentation Actually Decides

The chapters classify the preparation, not the molecule. USP 795 and 797 peptide documentation questions turn on one trigger: whether the finished preparation must be sterile at the point of administration. That single condition, not the peptide’s purity or its price tier, decides which chapter governs the record you are expected to hold.

Sterile routes sit under <797>. Injections, IV admixtures, ophthalmics, intrathecal preparations, and preparations for body cavities that do not communicate with the outside environment all fall on that side of the line. Nonsterile dosage forms, including oral liquids, capsules, creams, gels, and suppositories, fall under <795> (NCPA, USP Compounding Standards <795> and <797> presentation, 2026).

The boundary has a second edge that catches developers by surprise. A conventionally manufactured sterile product prepared strictly according to the manufacturer’s approved labeling is described as out of scope of <797>. Reconstituting a conventionally manufactured nonsterile product per its labeling for an individual patient, without storing it for future use, is not compounding under <795> (Mississippi Board of Pharmacy, <797> FAQ document, 2023).

Misclassifying a purchase is what turns a routine quality question into an escalation. Get the category wrong at the point of order and every downstream document request arrives against the wrong standard.

Research-Grade Supply, Development Support, and Compounding-Related Use: Drawing the Line

The category a peptide belongs to is set by its intended-use posture and labeling, not by how clean its chromatogram looks. A research-grade peptide supply chain exists to support laboratory and development work: the material is labeled for research use only, and that labeling is what establishes its status. A lot certificate of analysis showing identity and purity by HPLC and mass spectrometry documents the material itself. It does not, on its own, make that material permissible for compounding.

That distinction matters because the compounding pathway has its own entry conditions, and they differ between the two frameworks.

Under section 503A, a bulk drug substance may be used only if it complies with an applicable USP or NF monograph and the USP chapter on pharmacy compounding, or is a component of an FDA-approved drug product where no monograph exists, or appears on the 503A bulks list (FDA, Bulk Drug Substances Used in Compounding Under Section 503A, content current as of 2026-05-14). These are alternatives, not a checklist to satisfy in sequence. Separately, the substance must arrive with a valid certificate of analysis and must have been manufactured by an establishment registered with FDA under section 510 (FDA, content current as of 2026-05-14).

Outsourcing facilities operate under a narrower rule: a bulk drug substance may be used only if it appears on the 503B bulks list or is used to compound a drug on FDA’s drug shortages list at the time of compounding, distribution, and dispensing (FDA, Bulk Drug Substances Used in Compounding, content current as of 2026-03-26).

The recurring mistake is treating a purity figure as a category upgrade. A ≥98% HPLC result describes the lot, not its regulatory posture.

The Documentation Set: What a Defensible Record Actually Contains

A defensible record is not a folder of certificates. It is a set of artifacts where each one proves a specific obligation, and a reviewer can trace the chain from supplier lot to internal use lot without asking you a question.

The FDA guidance to compounders on knowing bulk suppliers frames the obligations directly: source API from FDA-registered facilities, hold valid certificates of analysis, and know what testing the supplier actually performs. Those three obligations map onto distinct records.

The chain-of-custody handoff is the artifact most often missing. Without it, a supplier lot number and an internal use lot number sit in separate systems with no recorded link, and a reviewer cannot confirm that the material in the vial is the material the COA describes.

Warning: The record that matters most is the one written when the numbers do not match. A discrepancy between in-house verification and the supplier COA, and the investigation that followed, is the document a quality reviewer will ask for first.

Identity Testing: Confirming the Molecule, Not Just the Mass

Identity testing is a separate control from purity, and a single intact-mass figure does not establish it. A mass that matches the expected molecular weight tells you something is present at that mass. It does not tell you the sequence is correct, that the counterion is what the label claims, or that the material is free of the non-peptide components that sit outside the peptide-related impurity thresholds.

Қызметтер The EMA guideline on development and manufacture of synthetic peptides draws that boundary explicitly. Impurities in synthetic peptides are grouped as peptide-related (truncations, deletions, oxidation, deamidation, sequence variants) and non-peptide (counterions, residual solvents and reagents such as TFA). Counterion identity and content, residual TFA, and water content are separate control items, not part of the peptide-related impurity thresholds. A peptide identity testing package that reports only the peptide-related side leaves three control items unaddressed.

Method conditions are what make an identity result evaluable. ICH Q2(R2) frames validation around specificity/selectivity, range, accuracy, and precision, with typical minimum experimental designs of 9 determinations across at least 3 concentration levels for accuracy and 9 determinations over 3 levels or 6 determinations at 100% of test concentration for precision. When assay and impurity share one test, the calibration range runs from the impurity reporting level up to 120% of the assay acceptance criterion.

So what does this mean for a supplier COA? An MS confirmation reported without method conditions cannot be evaluated. You cannot tell whether the method was specific to the sequence, what concentration levels were run, or whether the counterion was measured at all.

Purity Evaluation: Reading the Number Behind the Percentage

A purity percentage without method conditions, a chromatogram, and impurity context is not evaluable. “≥98%” from two suppliers can describe two different measurements, and peptide purity evaluation starts by asking what the number is measuring.

The threshold scale and the advertising scale are not the same scale. Under the Ph. Eur. general monograph “Substances for Pharmaceutical Use” referenced by the EMA guideline on the development and manufacture of synthetic peptides, peptide-related impurities are reported above 0.1%, identified above 0.5%, and qualified above 1.0%. Those are actions a manufacturer must take as impurity levels rise. A ≥98% HPLC figure is a headline result from one run, on one column, under one set of method conditions.

Typical reported COA practice for lyophilized synthetic peptides clusters around HPLC purity tiers of ≥95%, ≥98%, and ≥99%, intact-mass identity within about ±0.5 Da (or under 5 ppm on high-resolution instruments), water content roughly ≤5–8% by Karl Fischer, and retest or expiry windows of 12–24 months at −20 °C, as described in supplier COA-reading guides. These are industry-typical values that vary by supplier. They are not acceptance criteria, and treating them as such is the pitfall: a single percentage read as a purity specification.

Supplier Qualification: Scoring the Evidence, Not the Reputation

Peptide supplier qualification is an evidence-scoring exercise, not a reputation check. The criteria are the same ones the earlier sections defined: identity, тазалық, method conditions, lot linkage, and change control. Score each supplier against those criteria and the choice becomes defensible on paper.

Three supplier-side errors recur. A COA arrives without method conditions, so the purity figure cannot be reproduced. A certificate of origin arrives without lot linkage, so the material cannot be traced to the site that made it. A change-notification clause is absent from the agreement, so a specification change reaches the buyer after the fact.

FDA’s guidance to compounders on knowing your bulk suppliers and its conditions for 503A bulk drug substances both point the same direction: the buyer carries the burden of establishing that the source is acceptable and reliable, a responsibility USP <795> assigns to the designated person. That is the standard to score against.

Advanced: When In-House Verification Disagrees With the Supplier COA

If you already run in-house verification, this is the record that decides whether the disagreement is a supplier problem or a method problem. The distinction matters because the two failures route to different owners, and treating a method problem as a supplier problem burns a relationship you may need later.

Re-check method conditions and system suitability before you re-test the lot. Column chemistry, mobile phase composition, gradient, and detector settings all shift results, and a system suitability failure invalidates the run regardless of what the sample contains. Only after your system passes should you re-inject the lot.

Then compare your method against the supplier’s stated method. The ICH Q2(R2) guideline frames validation around specificity, accuracy, precision, and range, so if your method and the supplier’s differ on any of those characteristics, the two numbers are not measuring the same thing. Counterion identity and content, residual TFA, and water content are separate control items, and a gap in any of them can explain a purity delta without either party being wrong.

Document the discrepancy with both data sets attached, then route the outcome through your designated person.

The caution is a prerequisite, not a comment on your competence: this sequence only resolves a disagreement if your own method carries documented validation and a defined acceptance criterion. Without those two things, you have two uncalibrated numbers and no basis for deciding which one to trust.

Getting Started: The First Three Moves

The lowest-friction first action is not writing a new SOP. It is classifying every peptide lot you already hold, because the classification determines which documentation obligations apply at all. A lot that lands in the research-grade category carries a different evidence burden than one headed toward compounding-related use, and you cannot know which records are missing until each lot has a category.

Step 1: Classify the inventory. Run every existing lot through the classification table and mark its category. This is a desk exercise. It needs no supplier contact, no legal review, and no new template.

Step 2: Assemble what exists. For each lot in the compounding-related category, pull the certificate of analysis, the certificate of origin, and the lot linkage into one location, then mark what is absent. Missing items are findings, not failures. You are building the gap list that tells you where to spend effort.

Step 3: Score your suppliers. Take your top two or three suppliers through the qualification matrix, and open a change-notification conversation with any that score weakly. Suppliers who cannot answer a notification question in writing are telling you something useful before a quality question escalates.

The hesitation worth naming directly: this is not a compliance project that requires legal sign-off before it can begin. Classification and evidence-gathering are internal, reversible, and produce no external commitment. Start with the inventory, and let the gaps tell you what USP 795 and 797 peptide documentation work actually remains.

Frequently Asked Questions

What does the difference between USP <795> and <797> mean for a peptide purchase?

It decides which documentation standard your record has to satisfy, not which supplier you buy from. USP <795> governs nonsterile compounded preparations and USP <797> governs sterile ones, so the same peptide can sit under either chapter depending on the physical form and handling route it is destined for. Buyers should confirm the intended use category first, because that choice determines the identity, тазалық, and handling evidence the record must carry. Пептид өндірісі

Can a research-grade peptide with a ≥98% COA be used as a compounding ingredient?

Жоқ. A ≥98% purity figure describes the material’s assay result, not its suitability for a preparation, and research-grade supply is not manufactured or documented against compounding standards. The advertised percentage also says nothing about which impurities were detected, how they were identified, or whether they were qualified against a limit. Treat the research-grade label as a supply category, not as a compliance status.

What must a valid certificate of analysis contain?

A defensible COA names the specific lot, the analytical method used for each test, the acceptance criterion, and the measured result, so a reviewer can trace the number back to the method that produced it. A document that reports a single purity percentage with no method conditions, no lot identifier, and no raw output is a summary, not evidence. The record should also state who performed the testing and when.

Are identity testing and purity testing the same test?

Жоқ. Identity testing confirms the molecule is what the label says it is; purity testing measures how much of everything else is present. A sample can pass an identity check and still fail on impurity profile, which is why the two belong in separate rows of the documentation set rather than collapsed into one line.

How often should supplier qualification be repeated?

Requalification should be triggered by change, not by the calendar alone. A new lot, a revised method, a relocated manufacturing site, or a change in the supplier’s own specification all warrant a fresh review of the evidence. A periodic re-check adds value mainly as a backstop for suppliers whose change notifications are unreliable.

Does an RUO label alone settle the question?

Жоқ. The research-use-only designation limits the claims a supplier can make about the material; it does not by itself establish or exclude anything about the buyer’s intended use. What settles the question is the documented chain from the material’s stated grade through to the use category the buyer has already identified.

How do impurity reporting, identification, and qualification thresholds differ from advertised purity tiers?

They answer different questions. Reporting thresholds set the level at which an impurity must appear in the record at all; identification thresholds set the level at which its structure must be determined; qualification thresholds set the level at which it must be shown to be safe at the intended exposure. An advertised purity tier is a single headline number and carries none of that structure, which is why a high percentage and a clean impurity profile are not interchangeable claims.

Conclusion

USP 795 and 797 peptide documentation is decided by the preparation and its intended use, not by the paperwork you assemble afterward: the category comes first, and every record you keep has to answer to it. That is the spine this guide has followed throughout. You draw the line between research-grade supply, development support, and compounding-related use. You build a record set that can survive a question. You confirm the molecule by identity testing rather than by mass alone, you read the purity percentage against the method that produced it, and you score supplier evidence on what it actually shows instead of on reputation. When in-house verification disagrees with a supplier COA, the disagreement itself is information, and it belongs in the file.

What moves is the enforcement posture, not the compendial requirements. Inspection attention, documentation expectations, and the questions buyers ask tend to shift faster than the standards they are built on, so a record set that is defensible today is the one that stays defensible when the scrutiny changes. Build for the requirement, not for the current mood.

This article is an educational overview. It is not legal, regulatory, or compliance advice, and it does not describe compounding services or compounded preparations. Consult qualified regulatory counsel or a licensed pharmacist for determinations about your own operations. MOL Changes operates in the peptide and life-sciences supply space, so treat this as a neutral commercial-interest disclosure rather than an independent assessment.

Next steps

If you want to compare your current documentation set against the five-part framework above, request the analytical documentation package or speak with a technical specialist about the records that accompany your materials.